QTRX Stock Analysis: Quanterix | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 187m USD | 12M Return: -33.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.41M
Qual. Beats: 1
Rev. Trend: 85.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Quanterix Corporation (QTRX) is a U.S.-based life sciences company that develops and commercializes ultra-sensitive protein detection instruments and consumables built around its proprietary Simoa (Single Molecule Array) technology. Its product portfolio includes the HD-X, SR-X, and SP-X instrument platforms, along with associated assays, reagents, and replacement parts, and the company also provides contract research and clinical laboratory testing services through its Lucent Diagnostics offering.
The company primarily serves the neurology, oncology, and immunology/inflammation research markets, selling to academic and governmental laboratories, as well as pharmaceutical, biotechnology, and contract research organizations through a combination of direct field sales and third-party distributors. As a participant in the Life Sciences Tools & Services sub-industry, Quanterix follows a classic instrument-and-consumable (razor/blade) business model, where installed platforms generate recurring revenue from assay kits and reagents.
Quanterix was incorporated in 2007 (formerly Digital Genomics, Inc.) and is headquartered in Billerica, Massachusetts. It trades on NASDAQ as a micro-cap stock following its December 2017 IPO.
- Simoa instrument placements accelerate consumables revenue growth
- Biotech funding weakness pressures academic and pharma orders
- Lucent Diagnostics expansion lifts clinical services mix
| Net Income: -104.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -14.28 > 1.0 |
| NWC/Revenue: 93.75% < 20% (prev 220.0%; Δ -126.2% < -1%) |
| CFO/TA -0.22 > 3% & CFO -81.5m > Net Income -104.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.0m) vs 12m ago 21.34% < -2% |
| Gross Margin: 44.18% > 18% (prev 59.14%; Δ -14.96% > 0.5%) |
| Asset Turnover: 37.97% > 50% (prev 33.77%; Δ 4.19% > 0%) |
| Interest Coverage Ratio: -161.2 > 6 (EBIT TTM -105.7m / Interest Expense TTM 656k) |
| A: 0.37 (Total Current Assets 185.7m - Total Current Liabilities 49.9m) / Total Assets 366.7m |
| B: -1.62 (Retained Earnings -594.8m / Total Assets 366.7m) |
| C: -0.28 (EBIT TTM -105.7m / Avg Total Assets 381.6m) |
| D: 3.34 (Book Value of Equity 282.1m / Total Liabilities 84.5m) |
| Altman-Z'' = -1.22 = CCC |
| DSRI: 0.88 (Receivables 26.8m/28.3m, Revenue 144.9m/133.9m) |
| GMI: 1.34 (GM 59.14% / 44.18%) |
| AQI: 5.34 (AQ_t 0.39 / AQ_t-1 0.07) |
| SGI: 1.08 (Revenue 144.9m / 133.9m) |
| TATA: -0.06 (NI -104.2m - CFO -81.5m) / TA 366.7m) |
| Beneish M = -0.19 (Cap -4..+1) = D |
As of July 12, 2026, the stock is trading at USD 3.88 with a total of 356,381 shares traded. Over the past week, the price has changed by -10.39%, over one month by +26.38%, over three months by +15.48% and over the past year by -33.73%.
Current recommended Stop Loss: 3.40 (which is 12.4% or 1.4 ATR below the current price).
Quanterix has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold QTRX.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.3 | 11.6% |
P/S = 1.2932
P/B = 0.6461
Revenue TTM = 144.9m USD
EBIT TTM = -105.7m USD
EBITDA TTM = -84.7m USD
Long Term Debt = 27.4m USD (estimated: total debt 35.3m - short term 7.93m)
Short Term Debt = 7.93m USD (from shortTermDebt, last quarter)
Debt = 35.3m USD (from shortLongTermDebtTotal, last quarter) (leases 35.3m already included)
Net Debt = -63.9m USD (calculated: Debt 35.3m - CCE 99.3m)
Enterprise Value = 123.6m USD (187.5m + Debt 35.3m - CCE 99.3m)
Interest Coverage Ratio = -161.2 (Ebit TTM -105.7m / Interest Expense TTM 656k)
EV/FCF = -1.49x (Enterprise Value 123.6m / FCF TTM -82.9m)
FCF Yield = -67.10% (FCF TTM -82.9m / Enterprise Value 123.6m)
FCF Margin = -57.22% (FCF TTM -82.9m / Revenue TTM 144.9m)
Net Margin = -71.92% (Net Income TTM -104.2m / Revenue TTM 144.9m)
Gross Margin = 44.18% ((Revenue TTM 144.9m - Cost of Revenue TTM 80.9m) / Revenue TTM)
Gross Margin QoQ = 42.75% (prev 45.69%)
Tobins Q-Ratio = 0.34 (Enterprise Value 123.6m / Total Assets 366.7m)
Interest Expense / Debt = 1.86% (Interest Expense 656k / Debt 35.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -83.5m (EBIT -105.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 185.7m / Total Current Liabilities 49.9m)
Debt / Equity = 0.13 (Debt 35.3m / totalStockholderEquity, last quarter 282.1m)
Debt / EBITDA = 0.76 (negative EBITDA) (Net Debt -63.9m / EBITDA -84.7m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -63.9m / FCF TTM -82.9m)
Total Stockholder Equity = 296.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.30% (Net Income -104.2m / Total Assets 366.7m)
RoE = -35.17% (Net Income TTM -104.2m / Total Stockholder Equity 296.2m)
RoCE = -32.68% (EBIT -105.7m / Capital Employed (Equity 296.2m + L.T.Debt 27.4m))
RoIC = -26.32% (negative operating profit) (NOPAT -83.5m / Invested Capital 317.5m)
WACC = 8.89% (E(187.5m)/V(222.8m) * Re(10.29%) + D(35.3m)/V(222.8m) * Rd(1.86%) * (1-Tc(0.21)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.03%
[DCF] Fair Price = unknown (Cash Flow -82.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 85.12 | Revenue CAGR: 7.40% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=+3.22% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.29 | Chg30d=+20.36% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.23 | Chg30d=+40.87% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+22.3%
EPS next Year (2027-12-31): EPS=-1.36 | Chg30d=+28.80% | Revisions=-25% | GrowthEPS=-10.6% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: +0% (up=2, down=2)